Detail of the clinical trial

Title of the trial A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA
EudraCT number 2017-002822-19
Protocol number B1371019
Sponsor Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States of America
Indications Hemato-oncology
Diagnosis Myeloid leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2018
Date of approval by Institute (SÚKL) 13.7.2018
Date of approval by EC 7.2.2018
Date of initiation CT in ČR 24.9.2018
Date of ending CT in ČR
Notice
Sites Ústav hematologie a krevní transfuze, U Nemocnice 2904/1,Praha 2,128 20 (discontinued)
Fakultní nemocnice Královské Vinohrady,Interní hematologická klinika,Šrobárova 1150/50,Praha 10,100 34
Fakultní nemocnice Brno,Interní hematologická a onkologická klinika,Jihlavská 20,Brno,625 00
Fakultní nemocnice Ostrava,Klinika hematoonkologie,17. listopadu 1790/5,Ostrava - Poruba,708 52

‹‹ Back to list